Follica lands $5.5M in first round

Boston-based Follica has landed $5.5 million in its first round of financing. Interwest Partners led the round and existing investors PureTech Ventures also contributed. Follica is developing a therapy for androgenetic alopecia and other hair follicle disorders. The company will use to funding to complete a clinical proof of concept study.

"There is a great need for novel therapies; androgenetic alopecia begins as early as the teenage years or twenties, and affects about half the men and women in the United States by the age of 50," noted Follica co-founder Vera Price.

- see this release for more

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.